Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Current Taxes (2023 - 2025)

Catalyst Pharmaceuticals' Current Taxes history spans 3 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Current Taxes rose 56.15% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, up 56.15%, while the annual FY2025 figure was $1.4 million, 56.15% up from the prior year.
  • Current Taxes reached $1.4 million in Q4 2025 per CPRX's latest filing, up from $710000.0 in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $11.1 million in Q1 2025 to a low of $15000.0 in Q2 2024.
  • Average Current Taxes over 3 years is $2.2 million, with a median of $729000.0 recorded in 2023.
  • Peak YoY movement for Current Taxes: increased 22.63% in 2024, then soared 2826.67% in 2025.
  • A 3-year view of Current Taxes shows it stood at $729000.0 in 2023, then rose by 22.63% to $894000.0 in 2024, then surged by 56.15% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Current Taxes are $1.4 million (Q4 2025), $710000.0 (Q3 2025), and $439000.0 (Q2 2025).